Glaukos(GKOS) Stock Price Today | Quotes & News

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

GKOS Glaukos

Watchlist

104.230
-2.680-2.51%

Trading Mar 26 10:00 ET

5.90BMarket Cap-37.63P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Hospital Stocks Are Ready to Rebound, Deutsche Bank Says
BNN Bloomberg13:51 ET
Proposed Medicaid Cuts Would Devastate Local Economies: Report -- Barrons.com
Barron'sMar 25 00:01 ET
Breakeven On The Horizon For Glaukos Corporation (NYSE:GKOS)
Yahoo FinanceMar 24 09:11 ET
Healthcare Up as Traders Rotate to Less Inflation-Sensitive Sectors -- Health Care Roundup
Dow JonesMar 17 16:53 ET
Here's Why You Should Retain Glaukos Stock in Your Portfolio
Zacks Mar 13 06:05 ET
RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire: A Next-Generation Visual Field Solution
BusinesswireMar 11 07:00 ET

Comments

Teddy123

Mar 11 19:13

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

$Glaukos (GKOS.US)$
Glaukos Unveils Game-Changing Vision Diagnostic Wearable: First-Ever Platform for Glaucoma Testing

Teddy123

Feb 24 20:16

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa

$Glaukos (GKOS.US)$
Revolutionary Eye Treatment Advances: Can Glaukos Transform Keratoconus Care Without Surgery?

Moomoo AI

Jan 21, 2024 22:51

Glaukos' revenue growth is the market's focus due to its unprofitability. The 88% share price gain is solid, not standout. Market sentiment is lukewarm, hinting at potential stronger growth trends. Recent sentiment is positive due to strong share price momentum.

Investors Bid Glaukos (NYSE:GKOS) up US$137m Despite Increasing Losses YoY, Taking One-year Return to 88%

Meltyy

Dec 19, 2023 15:33

PDUFA Update…

Last week’s PDUFAs:
$Arcutis Biotherapeutics (ARQT.US)$ : Approved 12/15
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co (MRK.US)$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos (GKOS.US)$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co (MRK.US)$ : Approved ...

Meltyy

Dec 4, 2023 15:48

PDUFA Events for December 2023

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics (CRSP.US)$ $Vertex Pharmaceuticals (VRTX.US)$ $OptiNose (OPTN.US)$ $Arcutis Biotherapeutics (ARQT.US)$ $Calliditas Therapeutics (CALT.US)$ $bluebird bio (BLUE.US)$ $Glaukos (GKOS.US)$ $Ionis Pharmaceuticals (IONS.US)$ $Amgen (AMGN.US)$ $Merck & Co (MRK.US)$

GKOS Glaukos

Trade Overview

Capital Trend

News

Comments

Market Insights